NYSE$BHC
Bausch Health Companies Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Bausch Health reported a sixth consecutive quarter of year-over-year growth in both revenue and Adjusted EBITDA, with growth in all segments.
Bausch Health announced its third quarter 2024 financial results, achieving a 12% increase in consolidated revenues to $2.51 billion and a 10% rise in Adjusted EBITDA to $909 million. The company also raised its full-year 2024 guidance.
- Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA.
- Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis.
- Consolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 million.
- Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. of $909 million, up 10%.
Headline financials
Revenue & EPS history
Bausch Health · Revenue · Quarterly
$2.51B
Revenue by segment
Bausch Health · $1.88B total across 3 segments · Q3 2023
- Bausch + Lomb/International$1.01B+6.9%53.6%
- Salix$614M+12.9%32.7%
- Diversified Products$259M+8.8%13.8%
Forward guidance
The Company raised its consolidated full-year Revenue and Adjusted EBITDA guidance:
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+0.2%
Avg return
Earnings day
-0.6%
Avg return
5 days after
-1.9%
Avg return
30 days after
51%
35 / 68 earnings
Positive
+30.6%
Q1 2017
Best reaction
-21.5%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +10.9% | +0.9% | -4.1% | |
| Q4 2025 | -4.5% | -2.7% | -19.1% | |
| Q3 2025 | +12.4% | +14.2% | +7.6% | |
| Q1 2025 | +0.0% | -10.6% | -14.5% | |
| Q4 2024 | +10.3% | +15.8% | +10.0% | |
| Q3 2024 | +12.7% | +13.5% | +2.6% | |
| Q2 2024 | -6.6% | -10.6% | -1.7% | |
| Q1 2024 | -10.6% | -15.3% | -25.0% | |
| Q4 2023 | +5.9% | +5.9% | +10.3% | |
| Q3 2023 | +6.9% | +2.4% | +4.0% | |
| Q2 2023 | -2.9% | -4.6% | -9.3% | |
| Q1 2023 | -21.2% | -20.8% | +11.2% | |
| Q4 2022 | +10.8% | +7.8% | -16.3% | |
| Q3 2022 | +7.5% | +8.4% | +21.4% | |
| Q2 2022 | -3.3% | +2.9% | +14.7% | |
| Q1 2022 | -21.5% | -16.0% | -35.0% | |
| Q4 2021 | -1.9% | +1.9% | -3.3% | |
| Q3 2021 | -4.5% | -1.9% | -17.8% | |
| Q2 2021 | -15.5% | -10.1% | -0.7% | |
| Q1 2021 | -10.8% | -10.6% | +0.9% | |
| Q4 2020 | -0.9% | +0.6% | -1.8% | |
| Q3 2020 | -3.1% | -4.0% | +11.0% | |
| Q2 2020 | -7.2% | -9.2% | -16.3% | |
| Q1 2020 | -1.8% | +0.2% | +12.4% | |
| Q4 2019 | -5.8% | -7.3% | -51.3% | |
| Q3 2019 | +0.8% | +1.1% | +10.6% | |
| Q2 2019 | -4.0% | -3.0% | -6.9% | |
| Q1 2019 | +8.7% | +8.0% | -9.0% | |
| Q4 2018 | -6.7% | -7.3% | -2.0% | |
| Q3 2018 | +6.1% | +6.4% | -5.2% | |
| Q2 2018 | +5.4% | -2.9% | -7.3% | |
| Q1 2018 | +11.5% | +14.8% | +37.4% | |
| Q4 2017 | -17.5% | -16.8% | -13.9% | |
| Q3 2017 | +23.6% | +27.7% | +46.4% | |
| Q2 2017 | -8.5% | -9.6% | -12.9% | |
| Q1 2017 | +30.6% | +40.0% | +36.6% | |
| Q4 2016 | -18.7% | -21.8% | -33.7% | |
| Q3 2016 | -15.9% | -5.9% | -19.3% | |
| Q2 2016 | +21.7% | +11.0% | +33.5% | |
| Q1 2016 | -17.1% | -16.3% | -18.6% | |
| Q4 2015 | -7.4% | — | — | |
| Q3 2015 | -17.4% | — | — | |
| Q2 2015 | +5.4% | — | — | |
| Q1 2015 | +5.6% | — | — | |
| Q4 2014 | +14.7% | — | — | |
| Q3 2014 | +8.5% | — | — | |
| Q2 2014 | -6.1% | — | — | |
| Q1 2014 | -1.6% | — | — | |
| Q4 2013 | -1.0% | — | — | |
| Q3 2013 | +2.0% | — | — | |
| Q2 2013 | +6.2% | — | — | |
| Q1 2013 | +1.8% | — | — | |
| Q4 2012 | +1.3% | — | — | |
| Q3 2012 | -2.6% | — | — | |
| Q2 2012 | +2.2% | — | — | |
| Q1 2012 | +2.1% | — | — | |
| Q4 2008 | +6.3% | — | — | |
| Q4 2010 | +6.3% | — | — | |
| Q4 2011 | +6.3% | — | — | |
| Q3 2011 | -2.9% | — | — | |
| Q2 2011 | +3.9% | — | — | |
| Q1 2010 | +0.0% | — | — | |
| Q1 2011 | +6.3% | — | — | |
| Q3 2010 | -5.4% | — | — | |
| Q3 2009 | -5.4% | — | — | |
| Q2 2009 | +2.0% | — | — | |
| Q2 2010 | +2.0% | — | — | |
| Q4 2009 | +2.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro